Published in J Neurol Neurosurg Psychiatry on June 01, 1996
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
Central motor conduction in patients with anti-ganglioside antibody associated neuropathy syndromes and hyperreflexia. J Neurol Neurosurg Psychiatry (2002) 0.89
Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (1997) 0.88
Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol (2009) 0.77
Single fibre electromyography in multifocal motor neuropathy with persistent conduction blocks. J Neurol Neurosurg Psychiatry (1998) 0.75
Manipulating the immune system with immune globulin. N Engl J Med (1992) 2.75
IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol (1990) 2.67
Multifocal motor neuropathy: response to human immune globulin. Ann Neurol (1993) 2.32
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 2.12
High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology (1993) 2.02
Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology (1992) 1.93
The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology (1990) 1.87
Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol (1993) 1.75
Multifocal demyelinating neuropathy with persistent conduction block. Neurology (1982) 1.69
The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve (1994) 1.56
Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol (1994) 1.52
Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol (1991) 1.38
Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1995) 1.31
The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry (1985) 1.25
Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol (1992) 1.23
Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve (1988) 1.23
Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol (1990) 1.21
Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol (1991) 1.20
Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology (1994) 1.18
A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol (1990) 1.17
Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology (1992) 1.16
Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol (1986) 1.15
Different ceramide compositions of gangliosides between human motor and sensory nerves. J Neurochem (1990) 1.10
A syndrome of asymmetric limb weakness with motor conduction block. Neurology (1990) 1.08
Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry (1994) 1.08
Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve (1994) 1.07
Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry (1995) 1.06
Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology (1988) 1.06
Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology (1986) 1.03
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. Muscle Nerve (1995) 1.01
Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve (1993) 0.99
Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology (1995) 0.97
Motor neuron disease in a patient with a monoclonal IgMk directed against GM1, GD1b, and high-molecular-weight neural-specific glycoproteins. Ann Neurol (1990) 0.95
Cloning of human anti-GM1 antibodies from motor neuropathy patients. Ann Neurol (1994) 0.92
Delayed rectifier current of bullfrog sympathetic neurons: ion-ion competition, asymmetrical block and effects of ions on gating. J Physiol (1997) 0.92
Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy. Neurology (1990) 0.91
Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Ann Neurol (1995) 0.91
Antiglycolipid antibodies in peripheral neuropathy: fact or fiction? J Neurol Neurosurg Psychiatry (1994) 0.90
Neuropathy with onion bulb formations and pure motor manifestations. Can J Neurol Sci (1989) 0.90
Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol (1990) 0.90
Antiganglioside antibodies do not necessarily play a role in multifocal motor neuropathy. Muscle Nerve (1994) 0.89
Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin. Neurology (1994) 0.89
Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology (1994) 0.88
Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve (1995) 0.87
Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve (1993) 0.85
Persistent and transient "conduction block" in motor neuron diseases. Muscle Nerve (1993) 0.84
Separating motor neuron diseases from pure motor neuropathies. Multifocal motor neuropathy with persistent conduction block. Adv Neurol (1991) 0.83
Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers. Neurology (1994) 0.83
Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis and neuropathies. Muscle Nerve (1991) 0.82
Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (1994) 0.81
Motor neuropathy with multifocal conduction blocks. Muscle Nerve (1989) 0.80
Intravenous immunoglobulin for multifocal motor neuropathy. Lancet (1992) 0.80
Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology (1995) 0.79
Do GM1 antibodies induce demyelination? Muscle Nerve (1994) 0.79
Multifocal motor neuropathy or CIDP? Ann Neurol (1993) 0.78
Immunosuppressive treatment in lower motor neuron syndrome with autoantibodies against GM1 ganglioside. Eur Neurol (1993) 0.78
Motor neuropathy with multifocal persistent conduction blocks. Muscle Nerve (1992) 0.77
Chronic multifocal demyelinating neuropathy simulating motor neuron disease. Ital J Neurol Sci (1991) 0.77
Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy. Neurology (1999) 2.01
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2009) 1.47
Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology (1984) 1.30
Motoneuron-disease-like disorder after ganglioside therapy. Lancet (1991) 1.26
Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci (1999) 1.25
Cerebral ischaemia after nifedipine treatment. Br Med J (Clin Res Ed) (1981) 1.25
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol (2006) 1.04
Progressive cytochrome c oxidase deficiency in a case of Kearns-Sayre syndrome: morphological, immunological, and biochemical studies in muscle biopsies and autopsy tissues. Ann Neurol (1987) 1.01
Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology (1987) 0.99
Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry (2010) 0.96
How long is IVIg effective in multifocal motor neuropathy? Neurology (2004) 0.95
Neuropathy and anti-myelin-associated glycoprotein IgM M proteins: T cell regulation of M protein secretion in vitro. Ann Neurol (1985) 0.93
Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med (1990) 0.93
Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol (2011) 0.93
Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. Neurol Sci (2012) 0.92
Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann Neurol (1985) 0.89
Long-term effect of rituximab in anti-mag polyneuropathy. Neurology (2008) 0.89
Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (1997) 0.88
Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain (2002) 0.87
Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve (1996) 0.87
Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol (1996) 0.87
Long term disability and social status change after Guillain-Barré syndrome. J Neurol (2005) 0.86
Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology (1984) 0.85
Peripheral neuropathy in IgM monoclonal gammopathy and Wäldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol (1994) 0.85
Detection of CSF 14-3-3 protein in Guillain-Barré syndrome. Neurology (2006) 0.84
Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci (1999) 0.83
Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology (2001) 0.83
Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol (1996) 0.83
Low-grade non-Hodgkin B-cell lymphoma presenting as sensory neuropathy. Eur Neurol (1996) 0.82
Specificity of human IgM M-proteins that bind to myelin-associated glycoprotein: peptide mapping, deglycosylation, and competitive binding studies. J Immunol (1984) 0.82
Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev (2007) 0.82
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev (2006) 0.82
Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev (2003) 0.81
Expression of glycosylated recombinant human myelin-associated glycoprotein on a neuroblastoma cell line and its reactivity with HNK-1 but not human anti-MAG antibodies. Neurosci Lett (1998) 0.81
Criteria for early detection of conduction block in multifocal motor neuropathy (MMN): a study based on control populations and follow-up of MMN patients. J Neurol (1997) 0.81
Antibodies to GM1(NeuGc) in Guillain-Barré syndrome after ganglioside therapy. J Neurol Sci (2000) 0.81
Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a renal transplant recipient. Transpl Int (1998) 0.81
Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur J Neurol (2015) 0.80
Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol (1995) 0.80
Multifocal motor neuropathy: a source of error in the serial evaluation of conduction block. Muscle Nerve (1996) 0.80
Deterioration of multifocal motor neuropathy after plasma exchange. Neurology (1998) 0.80
Peripheral nervous system involvement in essential cryoglobulinemia and nephropathy. Clin Exp Rheumatol (1990) 0.79
Antisulfatide polyneuropathy: antibody-mediated complement attack on peripheral myelin. Acta Neuropathol (1998) 0.78
Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci (2000) 0.78
Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci (1998) 0.77
Occurrence and characterization of Pain in immune-mediated neuropathies: a multicentre prospective study. Eur J Neurol (2011) 0.77
Failure to detect anti-MAG antibodies by RIA in CSF of patients with multiple sclerosis. J Neuroimmunol (1986) 0.77
Immunosuppressive treatment for multifocal motor neuropathy. Cochrane Database Syst Rev (2002) 0.77
Lumbosacral root and facial nerve enhancement in Miller Fisher syndrome. J Neurol (1998) 0.77
Anti-MAG IgM antibodies in patients with neuropathy and IgM M proteins: detection by ELISA. Neurology (1983) 0.77
Anti-GM1/GD1b M-proteins damage human spinal cord neurons co-cultured with muscle. J Neurol Sci (1993) 0.76
Visual evoked potentials in patients with neuropathy and macroglobulinemia. Ann Neurol (1987) 0.76
Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol (1999) 0.76
Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. J Neuroimmunol (1999) 0.76
Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev (2005) 0.76
Small fibre involvement in neuropathy associated with IgG, IgA and IgM monoclonal gammopathy. Electromyogr Clin Neurophysiol (1995) 0.76
POEMS syndrome with IgA lambda monoclonal gammopathy. Haematologica (1990) 0.75
The anti-oligosaccharide antibodies present in sera from patients with motor neuron disease and neuropathy recognize the N-glycolylneuraminic acid containing gangliotetrahexosyl oligosaccharide. Glycoconj J (1995) 0.75
Studies on anti-myelin antibodies in patients with multiple sclerosis. Riv Neurol (1987) 0.75
Anti-MAG antibody and antibody complexes: detection by radioimmunoassay. Neurology (1985) 0.75
Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. J Neuroimmunol (2001) 0.75
Acute hand weakness as a regional variant of Guillain-Barré syndrome. Eur J Neurol (2009) 0.75
Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. J Neurol Sci (1995) 0.75
Transient response to immune therapies in post-irradiation lumbosacral radiculoplexopathy. J Neurol (2004) 0.75